Results 51 to 60 of about 34,922 (258)

Engineered 3D cultured human nasal mucosa mesenchymal stem cell derived sEVs for targeted brain‐derived neurotrophic factor delivery to enhance neurogenesis and attenuate brain damage

Interdisciplinary Medicine, EarlyView.
This study successfully developed and evaluated BDNF@RVG‐sEVs, a novel brain‐targeted nanomedicine based on hnmMSC‐derived sEVs, designed to overcome the BBB and enhance neurorestoration. By integrating RVG for enhanced brain targeting and encapsulating BDNF for potent neurorepair, our system address the key limitations of the conventional sEVs and ...
Xueting Wang, Junge Chen, Jiao Xia, Weitong Yang, Teng Ma, Tianzi Shan, Weifeng He, Gaoman Zhang, Zhuoran Xia, Weiwei Wang, Zhusheng Liu, Zhiqiang Yi, Piye Niu, Tian Chen   +13 more
wiley   +1 more source

Extended-release oral capsule of carbidopa–levodopa in Parkinson disease

Therapeutic Advances in Neurological Disorders, 2018
Motor fluctuations complicate the treatment of patients with Parkinson’s disease receiving levodopa. Extended-release carbidopa–levodopa has a pharmacokinetic profile that provides a more continuous levodopa serum concentration.
Jason Margolesky, Carlos Singer
doaj   +1 more source

The effects of royal jelly on human health: A narrative review of clinical studies

JSFA reports, EarlyView.
Abstract Royal jelly (RJ) is a natural bioactive substance with documented effects on human health. This narrative review synthesizes evidence from clinical and clinically relevant experimental studies evaluating the therapeutic potential of RJ.
Georgios Goras, Andreas Thrasyvoulou, Evanthia Tsilimpokou   +2 more
wiley   +1 more source

Intrastriatal Memantine Infusion Dampens Levodopa-Induced Dyskinesia and Motor Deficits in a Mouse Model of Hemiparkinsonism

Frontiers in Neurology, 2019
Although the administration of dopamine precursor levodopa remains as the mainstay for the treatment of Parkinson's disease, long-term exposure to levodopa often causes a disabling complication, referred to as levodopa-induced dyskinesias. Therefore, the
Masatoshi Ogawa, Masatoshi Ogawa, Yu Zhou, Yu Zhou, Ryosuke Tsuji, Ryosuke Tsuji, Jiro Kasahara, Jiro Kasahara, Satoshi Goto, Satoshi Goto   +9 more
doaj   +1 more source

Effect of Rectal Levodopa Administration: A Case Report

Case Reports in Neurology, 2015
Objective: The aim of this report is to discuss whether or not rectal levodopa administration is useful in some situations. Background: In situations where oral intake of levodopa formulations is not possible, the treatment options of Parkinson's disease
Jolanda M.J. Vogelzang, Marianne Luinstra, A. Wijnand F. Rutgers   +2 more
doaj   +1 more source

Voice and Speech in Atypical Parkinsonian Disorders

Movement Disorders Clinical Practice, EarlyView.
Background Motor speech disorders are early, common, and functionally limiting features of atypical parkinsonian disorders (APDs) such as progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy (MSA). These impairments are underrecognized and undertreated in neurology clinics.
Federico Rodriguez‐Porcel, Farwa Ali, Michiko Bruno, Heather Davis Cuevas, Rohit Dhall, Kylie Dunne‐Platero, Lawrence I. Golbe, Ihtsham Haq, Nicole Herndon, Lawrence S. Honig, Kyurim Kang, Sarah Kremen, Guillaume Lamotte, Nikolaus R. McFarland, Michela Mir, Leila Montaser‐Kouhsari, Alexander Pantelyat, Joel Page, Hylan Pickett, Laura Purcell Verdun, Kelly Richardson, Jessica Shurer, Michelle Troche, Rene L. Utianski, Katya Villarreal‐Cavazos, Tuhin Virmani, Anne‐Marie Wills, as the Diagnosis and Treatment Working Group, CurePSP Center of Care (CoC) Network, Farwa Ali, Michiko Bruno, Timothy Chang, Rohit Dhall, Kimiko Domoto‐Reilly, Lawrence I. Golbe, Ihtsham Haq, Lawrence S. Honig, Sarah Kremen, Guillaume Lamotte, Zoltan Mari, Nikolaus R. McFarland, Leila Montaser‐Kouhsari, Alexander Pantelyat, Federico Rodriguez‐Porcel, Junaid Siddiqui, Jessica Shurer, Christopher Spears, Tuhin Virmani, Anne‐Marie Wills   +48 more
wiley   +1 more source

Risk‐Benefit Considerations in Deep Brain Stimulation Discontinuation for Late‐Stage Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
ABSTRACT Background Management of deep brain stimulation (DBS) in late‐stage Parkinson's disease (LSPD) remains challenging, particularly when deciding whether to continue or discontinue stimulation, and evidence on risk–benefit considerations is limited. Objectives To identify key factors to improve decision‐making in DBS management for LSPD patients.
Pietro Antenucci, Andrea Gozzi, Fabiana Colucci, Federica Pes, Jay Guido Capone, Alba Scerrati, Michele Alessandro Cavallo, Maura Pugliatti, Daniela Gragnaniello, Mariachiara Sensi   +9 more
wiley   +1 more source

Contribution of dopaminergic polymorphisms to levodopa treatment response and drug concentration in Chinese patients with Parkinson’s disease

Clinical Parkinsonism & Related Disorders
Background: Levodopa is the mainstay of treatments for Parkinson’s disease (PD), but large heterogeneity exists in patient response. Pharmacogenetic studies highlighted that genetic factors may play a relevant influence in this drug response variability.
Xiaoqin He, Kai Shi, Chengjun Mo, Yi Zhang, Qin Xiao, Xiaodong Yang   +5 more
doaj   +1 more source

Subthalamic Nucleus Deep Brain Stimulation Improves Kinetic Tremor in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Although resting tremor is a characteristic feature of Parkinson's disease (PD), many patients also suffer from action tremor. Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is effective in reducing motor symptoms. However, it is unclear to what extent STN‐DBS improves action tremor in PD, particularly kinetic tremor.
Iwan Grooters, Bart E.K.S. Swinnen, Yarit Wiggerts, Maarten Bot, Pepijn van den Munckhof, P. Rick Schuurman, Martijn Beudel, Rob M.A. de Bie, Arthur W.G. Buijink   +8 more
wiley   +1 more source

Levodopa influence on turning dynamics in people with Parkinson’s disease

Scientific Reports
Turning behaviors are affected in people with Parkinson’s disease (PwPD) leading to falls and Freezing of Gait (FOG). Levodopa therapy is commonly recommended for PwPD to help alleviate motor symptoms.
Lakshmi Pillai, Reid D. Landes, Tuhin Virmani   +2 more
doaj   +1 more source